New Published Clinical Trial Results Confirm that PleuraFlow Enables Improved Quality and Cost of Care for Cardiac Surgery Patients

New Published Clinical Trial Results Confirm that PleuraFlow Enables Improved Quality and Cost of Care for Cardiac Surgery Patients Reduction of Patient Complications and Hospital Resource Utilization After Heart Surgery Demonstrated with Use of the PleuraFlow ACT System Irvine, CA – November 20, 2019 — ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results published in the peer-reviewed Journal of Cardiothoracic Surgery. The trial evaluated the use of the PleuraFlow® Active Clearance Technology® (ACT®) System in prevention of retained blood complications in heart surgery patients. PleuraFlow is a medical device used at the bedside in the ICU that enables caregivers to proactively maintain

ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations

  ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations   Anaheim, California–May 7, 2019–ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results of its PleuraFlow® device were presented at the American Association for Thoracic Surgery (AATS) 99th Annual meeting on May 4 in Toronto, Canada. This new data stems from a trial evaluating the use of ClearFlow’s PleuraFlow® Active Clearance Technology® (ACT®) System in heart surgery patients at the Montreal Heart Institute.   PleuraFlow is a medical device used at the bedside in the ICU that enables caregivers to actively maintain chest tube patency following cardiac surgery.